			AGADS LIMITED				
		ENT OF AUDITED	RESULTS FOR THE FINANCIAL YEAR ENDED 31 MARCH 2017				
Statement of Comprehensive Income			Statement of Cash Flows				
	31 Mar. 2017 Shs'000'	31 Mar. 2016 Shs'000'		31 Mar. 2017 Shs'000'	31 Mar. 2016 Shs'000'		
Revenue Fair value (loss)/gain on biological assets Cost of production Gross profit	140,224 (1,279) (67,178) 71,767	126,012 3,487 (89,082) 40,417	Cash flow from operating activities before changes in working capital Changes in working capital Net cash generated from/(used in) operating activities Net cash used in investing activities Net cash used in financing activities	51,113 (51,045) 68 (26) (654)	13,381 (15,512) (2,131) (31)		
Other Income Administrative expenses	2,165 (41,720)	671 (31,397)	Decrease in cash and cash equivalents	(612)	(2,162)		
Profit before tax	32,212	9,691	Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the year	1,012 400	3,174		
Tax charge	(14,105)	(9,214)	· · · · · · · · · · · · · · · · · · ·		.,		
Profit for the year	18,107	477	Statement of Changes in Equity				
Other comprehensive income, net of tax	138,260	36,426		Share capital	Revaluation surplus	Retained earnings	Tota
Total comprehensive income for the year Basic and diluted earnings per share	156,367 0.56	36,903 0.01	At 1 April 2016	Share Capital Shs'000' 40,196	Shs'000' 478,004	Shs'000' 173,736	Shs'000 691,936
			Total comprehensive income for the year Transfer of excess depreciation Deferred income tax on transfer At 31 March 2017	40.196	138,260 (7,610) 	18,107 7,610 2,283 201,736	156,367 2,283 850,586
Statement of Finance	cial Position		The above are extracts from the Financial Statements that were approved by the Board of	Directors on 27 July 20	17. The accounts were a	udited by EY LLP, C	Certified
EQUITY Share capital Revaluation surplus Retained earnings	31 Mar. 2017 Shs'000' 40,196 608,654 201,736	31 Mar. 2016 Shs'000' 40,196 478,004 173,736	Public Accountants. PERFORMANCE During the year under review, the company made an after tax profit of Shs.18.1 million cori in revenue was mainly attributable to improved coffee prices despite a drop in coffee tons: 4.218 per kilogram compared to USD 3.863 per kilogram in 2015/2016. Production volume year, of which 315 tons had been sold prior to 31 March 2107 (2016: 318.9 tons). Coffee coffee due to the weather conditions, hence at the year end, the company remained with h	sold in the year. The aver sold in the year. The aver solution have a solution of the solution solution of the solution of the solution of the solution solution of the solution of the solution of the solution solution of the solution of t	rage price realized during m 326 tons in 2016 to 42 fee auction house were a	g the year increased 24 tons in the current	to USD t financial
Non-current liabilities Current liabilities Total equity and non-current liabilities REPRESENTED BY:-	850,586 60,716 11,500 922,802	691,936 48,912 20,317 761,165	The cost of production dropped by Shs. 21.9 million whilst administrative costs increased by approximately Shs. 10.3 million. The increase in administrative expenses was due to an increase in the depreciation charge for the year, following are revaluation of the company's property, plant and equipment towards the end of 2016. The decrease in costs of sales was as a result of enhanced cost efficiencies achieved in the farm. The other comprehensive income reflects the after tax revaluation surplus of the company's freehold land, measuring 44 hectares. The remaining land measuring 34 thectares is leasehold land and therefore not subjected to a valuation.				
Non-current assets Current assets	775,263 147,539 922,802	644,781 116,384 761,165	DIVIDEND Although the financial performance of the company improved during the current financial y distribution to shareholders, especially considering management's anticipation that, due to 2017/2018. The board of directors therefore do not recommend payment of a dividend for	the effects of the early s			

By the Order of the Board 27 July 2017

EAAGADS LIMITED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 MARCH 2017

	Notes	2017 Shs.'000	2016 Shs.'000
SALES	6	140,224	126,012
(LOSS) / GAIN ARISING FROM CHANGES IN FAIR VALUE OF BIOLOGICAL ASSETS AT FAIR VALUE LESS COSTS TO SELL	14	(1,279)	3,487
COST OF PRODUCTION	7	<u>(67,178)</u>	(89,082)
GROSS PROFIT		71,767	40,417
OTHER INCOME	8	2,165	671
ADMINISTRATIVE EXPENSES	9	(41,746)	(31,428)
NET FOREIGN EXCHANGE GAIN		26	31
PROFIT BEFORE TAX	10	32,212	9,691
TAX CHARGE	11(a)	(14,105)	<u>(9,214)</u>
PROFIT FOR THE YEAR		18,107	477
OTHER COMPREHENSIVE INCOME NOT TO BE RECLASSIFIED TO THE PROFIT OR LOSS IN SUBSEQUENT PERIOD, NET OF TAX:			
REVALUATION OF PROPERY, PLANT AND EQUIPMENT		145,537	52,037
DEFERRED TAX ON REVALUATION OF PROPERY, PLANT AND EQUIPMENT	22	(7,277)	<u>(15,611)</u>
NET ACTUARIAL LOSSES ARISING FROM CHANGES IN THE GRATUITY VALUATION TOTAL OTHER COMPREHENSIVE INCOME NET OF TAX	_	138,260 	36,426
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		156,367	36,903
EARNINGS PER SHARE	12	0.56	0.01

EAAGADS LIMITED Statement of Financial Position AS AT 31 MARCH 2017

	Notes	2017 Shs.'000	2016 Shs.'000		
NON-CURRENT ASSETS Property, plant and equipment Prepaid operating lease	13 15	775,048 <u>215</u>	644,566 <u>215</u>		
CURRENT ASSETS		775,263	644,781		
Biological assets Inventories Trade and other receivables Amounts due from related parties Corporation tax recoverable Cash and bank balances	14 16 17 18 11(c) 26	91,876 25,433 9,220 19,486 1,124 <u>400</u> <u>147,539</u>	93,155 1,395 8,608 3,265 8,949 <u>1.012</u> <u>116,384</u>		
TOTAL ASSETS EQUITY AND LIABILITIES Equity		<u>922,802</u>	<u>761,165</u>		
Share capital Revaluation reserve Retained earnings Total equity	19 20	40,196 608,654 <u>201,736</u> <u>850,586</u>	40,196 478,004 <u>173,736</u> <u>691,936</u>		
NON-CURRENT LIABILITIES Deferred tax liabilities Retirement benefit obligations Long service awards	22 23 24	55,532 5,130 <u>54</u> 60,716	44,257 4,601 <u>54</u> 48,912		
CURRENT LIABILITIES Retirement benefit obligations Long service awards Amounts due to related parties Trade and other payables TOTAL EQUITY AND LIABILITIES	23 24 18 25	2,164 348 1,075 <u>7,913</u> <u>11,500</u> <u>922,802</u>	865 348 17,659 <u>1.445</u> <u>20,317</u> <u>761,165</u>		
The financial statements were approved and authorised for issue by the Board of Directors on 2017 and signed on its behalf by:					

Director

Director

EAAGADS LIMITED Statement of changes in equity For the year ended 31 march 2017

EAAGADS LIMITED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH 2017

	Share	Revaluation	Retained	
	Capital	reserve	earnings	Total
	Kshs.'000	Kshs.'000	Kshs.'000	Kshs.'000
	(Note 19)	(Note 20)	(Note 21)	1313.000
	(1010-17)	(Note 20)	(NOIC 21)	
As at 1 April 2015	40.196	442,995	171,417	654,608
	,	,	,	
Profit for the year	-	-	477	477
Other comprehensive income		36,426		36,426
Total comprehensive income for the year	-	36,426	477	36,903
Transfer of excess depreciation	-	(1,417)	1,417	-
Deferred income tax on transfer			425	425
At 31 March 2016	<u>40,196</u>	478,004	<u>173,736</u>	<u>691,936</u>
At 1 April 2016	40,196	478,004	173,736	691,936
Profit for the year	-		18,107	18,107
Other comprehensive income		138,260		<u>138,260</u>
				_
Total comprehensive income for the year	-	137,144	18,107	156,367
Transfer of excess depreciation	-	(7,610)	7,610	-
Deferred income tax on transfer		<u> </u>	<u>2,283</u>	<u>2,283</u>
At 31 March 2017	<u>40,196</u>	608,654	201,736	<u>850,586</u>

The retained earnings represent accumulated surplus arising from other normal operating activities. These reserves are available for dividend distribution to the shareholders of the Company except for surplus arising from fair valuation of biological assets in line with IAS 41-Agriculture of Kshs. 19,245,620 (2016 : Kshs. 20,525,000).

EAAGADS LIMITED Statement of Cash Flows For the year ended 31 march 2017

	Notes	2017 Shs.'000	2016 Shs.'000
Cash flows from operating activities			
Profit before tax		32,212	9,691
Depreciation	13	15,054	6,958
Foreign exchange difference		26	31
Increase/(decrease) in retirement benefit obligations	23	2,542	188
(Loss) / gain arising from changes in fair value of biological assets less estimated costs to sell	14	<u>1,279</u>	<u>(3,487)</u>
Cash flows from operating activities before changes in working capital		51,113	13,381
Retirement benefits paid Increase in trade and other receivables	17	(714)	(649)
Decrease in amounts due to related parties	17	(612) (16,584)	(1,846) (28,144)
(Increase) /decrease in amounts due from related party balances		(16,364)	(28, 144)
(Increase)/decrease in inventories		(24,038)	1,841
Increase / (decrease) in trade and other payables		7,123	(500)
norease / (accrease) in radie and other payables		7,125	(500)
Net cash generated from operating activities		<u>68</u>	<u>(2,131)</u>
Net foreign exchange difference			
CASH FLOWS FROM FINANCING ACTIVITIES			
Unclaimed dividends		(654)	-
Net foreign exchange difference		(26)	(31)
NET DECREASE IN CASH AND CASH EQUIVALENTS		(612)	(2,162)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR		1,012	3,174
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	27	<u>400</u>	<u>1,012</u>